Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Rhea-AI Summary

Corvus Pharmaceuticals (NASDAQ: CRVS) will report results from cohort 4 of its randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT).

The company will host a conference call and live webcast with presentation slides; domestic dial-in is 1-800-717-1738 and international is 1-646-307-1865. The live webcast and slides are available via Corvus investor relations, and a replay will be available on the website for 60 days.

News Market Reaction – CRVS

+165.96% 1.6x vol

40 alerts

+165.96% News Effect

+22.6% Peak in 5 hr 33 min

+$381M Valuation Impact

$610M Market Cap

1.6x Rel. Volume

On the day this news was published, CRVS gained 165.96%, reflecting a significant positive market reaction. Argus tracked a peak move of +22.6% during that session. Our momentum scanner triggered 40 alerts that day, indicating elevated trading interest and price volatility. This price movement added approximately $381M to the company's valuation, bringing the market cap to $610M at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Webcast replay period: 60 days Cash & securities: $65.7M Q3 2025 net loss: $10.2M +5 more

8 metrics

Webcast replay period 60 days Duration replay will be available on company website

Cash & securities $65.7M As of Sept 30, 2025 (Q3 2025 10-Q)

Q3 2025 net loss $10.2M Quarter ended Sept 30, 2025

R&D expense $8.5M vs $5.2M Q3 2025 vs prior-year quarter

ATM program size $100M At-the-market offering capacity with no sales to date

Short interest 12.56% Reported short interest as a percent of float

CEO stock options 1,000,000 shares at $8.81 Option grant on Dec 4, 2025, expiring Dec 4, 2035

CBO stock options 100,000 shares at $8.81 Option grant on Dec 4, 2025, expiring Dec 4, 2035

Market Reality Check

Price: $18.26 Vol: Volume 1,812,149 is 1.11x...

normal vol

$18.26 Last Close

Volume Volume 1,812,149 is 1.11x the 20-day average 1,630,267, indicating elevated interest ahead of results. normal

Technical Shares at $7.14 trade above the 200-day MA of $5.63 and 25.63% below the 52-week high of $9.60.

Peers on Argus

CRVS gained 4.69% while close peers showed mixed moves: PRTA +1.09%, ATXS +2.07%...

CRVS gained 4.69% while close peers showed mixed moves: PRTA +1.09%, ATXS +2.07%, ITOS +0.10%, ALMS -1.35%, REPL -4.70%, pointing to a stock-specific setup around the trial update.

Historical Context

5 past events · Latest: Jan 05 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 05	Cohort 4 timing update	Positive	-7.2%	Confirmed January 2026 timing for cohort 4 atopic dermatitis results.
Dec 08	Clinical data update	Positive	-2.8%	Reported final Phase 1/1b soquelitinib T cell lymphoma efficacy and safety data.
Nov 04	Earnings and pipeline	Positive	-0.5%	Q3 2025 results plus multiple soquelitinib milestones and trial timelines.
Nov 03	Conference presentation	Positive	-4.5%	Announcement of final Phase 1/1b lymphoma data presentation at ASH 2025.
Oct 31	Investor conference	Neutral	+3.6%	Planned participation in Guggenheim Healthcare Innovation investor conference.

Pattern Detected

Recent CRVS news, especially around soquelitinib data and events, often preceded short-term price declines, with only one of the last five items seeing a positive next-day move.

Recent Company History

Over the past few months, Corvus has consistently highlighted soquelitinib as its key asset. The company completed enrollment in atopic dermatitis cohort 4 and flagged data for Jan 2026, while advancing a randomized Phase 3 trial in relapsed/refractory PTCL (target ≈150 patients). Final Phase 1/1b lymphoma data presented at ASH on Dec 8, 2025 showed encouraging PFS and OS. Financially, Q3 2025 cash of $65.7M was expected to fund operations into Q4 2026. Today’s announcement sets the specific date and call to disclose the long-awaited cohort 4 dermatitis results.

Market Pulse Summary

The stock surged +166.0% in the session following this news. A strong positive reaction aligns with ...

Analysis

The stock surged +166.0% in the session following this news. A strong positive reaction aligns with growing focus on soquelitinib’s role in atopic dermatitis, especially after prior oncology data and clearly signposted timelines. However, past news often saw weak or negative next-day moves, so enthusiasm could fade if cohort 4 results or guidance disappoint. Existing capital needs and reliance on external financing remain important when assessing how durable any move above prior levels might be.

Key Terms

placebo-controlled, phase 1, atopic dermatitis, t cell lymphoma, +4 more

8 terms

placebo-controlled medical

"randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib"

"Placebo-controlled" describes a testing method where one group receives the actual treatment or intervention, while another group receives a harmless, inactive version called a placebo. This approach helps determine whether the real treatment has genuine effects beyond psychological expectations. For investors, understanding this ensures confidence that reported benefits are real and not influenced by bias or false perceptions.

phase 1 medical

"placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients"

Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.

atopic dermatitis medical

"trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis"

A chronic inflammatory skin condition, often called eczema, that causes dry, itchy, red patches and recurring flare-ups; think of it as a persistent rash that can come and go over a person’s life. It matters to investors because its chronic nature and large patient population create steady demand for treatments, influence drug development and approval decisions, affect healthcare costs and reimbursement, and can drive revenue and valuation shifts for companies working on therapies and diagnostics.

t cell lymphoma medical

"Phase 1/1b T Cell Lymphoma trial"

T cell lymphoma is a group of cancers that start in T cells, the immune system’s front-line cells, causing them to grow abnormally and form tumors in blood, lymph nodes, skin or organs. It matters to investors because its rarity, severity and varied subtypes drive demand for effective diagnostics and treatments, influence clinical trial risk and regulatory timelines, and can materially affect the valuation of companies developing drugs, tests or therapies—think of it as a niche but high-impact market where a successful therapy can change a company’s prospects.

itk inhibition medical

"Biomarker data show ITK inhibition with Th1 skewing"

ITK inhibition is the blocking of a specific enzyme, interleukin-2-inducible T-cell kinase, that helps control how certain immune cells communicate and react. For investors, ITK inhibitors are potential drugs that can dial down overactive immune responses or reshape cancer-fighting immunity — like turning a volume knob or redirecting traffic — so progress or setbacks in this area can strongly affect a biotech’s prospects, market size and safety profile.

orphan drug regulatory

"soquelitinib has Orphan Drug and Fast Track designations"

A drug designated for an orphan disease is a medicine developed to treat a rare condition that affects only a small number of people. Regulators often give these drugs special incentives—such as reduced costs, faster review, and temporary exclusive selling rights—to encourage development, which matters to investors because those incentives can make a small market financially viable and reduce competition, much like a temporary patent on a niche product.

fast track regulatory

"soquelitinib has Orphan Drug and Fast Track designations"

A fast track designation is a regulatory label that speeds up the review and communication between a drug developer and regulators for treatments addressing serious illnesses or unmet medical needs. For investors, it matters because it can shorten development time and reduce regulatory delays—like getting a VIP lane at the airport—raising the chance of earlier market access and potential revenue, though it does not guarantee approval.

at-the-market program financial

"additional funding, including under its $100 million at-the-market program"

An at-the-market program is a way for a company to sell new shares of its stock gradually over time directly into the stock market, rather than all at once. This approach allows the company to raise money as needed while giving investors the opportunity to buy shares at current market prices. It helps manage the timing and price of new stock offerings, providing flexibility for both the company and investors.

AI-generated analysis. Not financial advice.

Company to host conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET / 5:00 am PT

SOUTH SAN FRANCISCO, Calif., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, announced that it will host a conference call and webcast on Tuesday, January 20, 2026 at 8:00 am ET (5:00 am PT) to report the results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis.

Conference Call, Webcast and Presentation Slides
The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) or by clicking on this link for instant telephone access to the event. The live webcast, which will include presentation slides, may be accessed via the investor relations section of the Corvus website. A replay of the webcast will be available on Corvus’ website for 60 days.

About Corvus Pharmaceuticals 
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is now in a registration Phase 3 clinical trial for relapsed/refractory PTCL and in a Phase 1 clinical trial for the treatment of atopic dermatitis. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements related to the timing of the announcement of the results from cohort 4 of the Company’s Phase 1 clinical trial evaluating soquelitinib in patients with moderate to severe atopic dermatitis. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT:
Leiv Lea
Chief Financial Officer
Corvus Pharmaceuticals, Inc.
+1-650-900-4522
llea@corvuspharma.com

MEDIA CONTACT:
Sheryl Seapy
Real Chemistry
+1-949-903-4750
sseapy@realchemistry.com

FAQ

When will Corvus (CRVS) announce cohort 4 Phase 1 soquelitinib results?

Corvus will report cohort 4 results on January 20, 2026 at 8:00 am ET (5:00 am PT).

How can investors join the Corvus (CRVS) conference call on January 20, 2026?

Dial 1-800-717-1738 (domestic) or 1-646-307-1865 (international) to access the conference call.

Where can I watch the Corvus (CRVS) webcast for the Phase 1 soquelitinib update?

The live webcast with presentation slides is available via Corvus’ investor relations website.

Will a replay of the Corvus (CRVS) webcast be available after the January 20 event?

Yes, a replay of the webcast will be posted on the company website and available for 60 days.

What trial data will Corvus (CRVS) present on January 20, 2026?

The company will present results from cohort 4 of the randomized, blinded, placebo-controlled Phase 1 trial of soquelitinib in moderate to severe atopic dermatitis.

Will Corvus (CRVS) provide presentation slides during the January 20 webcast?

Yes, the live webcast will include presentation slides accessible via the investor relations site.